Inside the research

Labcorp Holdings Inc.

LH Research profile · latest available data

Price overview

$309.64

▲ +0.69 (+0.2%)

52w hi$338.61
52w lo$244.17
Vol821.50K
As of25 Sep 2026

The Verdict

Buy

Our score +0.53

Short+0.42
Medium+0.65
Long+0.50

computed 2026-09-27

Key fundamentals

Labcorp Holdings Inc.

Healthcare · Diagnostics & Research

Market cap$25.11B
Enterprise value$31.81B
Trailing P/E25.63x
Forward P/E15.60x
EV / EBITDA13.71x
P / S (ttm)1.75x
Profit margin7.0%
Return on equity11.7%
Revenue growth+5.8%
Earnings growth+28.2%
Debt / equity79.12

Layer Breakdown

LayerRawContribution
Fundamental+0.28
Sector+0.08
Technical+0.35
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; a strategic alliance with the National Association of Community Health Centers to support current and emerging clinical leaders through the NACHC Leadership Exchange for Chief Medical Officers; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

United States · www.labcorp.com

Risk Metrics

Beta vs SPX0.54
Corr SPX0.37
Annual vol23.5%
Annual ret+19.3%
Sharpe0.82
Max DD-17.4%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$310.06
High / Low$340.00 / $270.00
Median$320.00
Analysts17
Strong Buy3
Buy12
Hold4
Sell0
Strong Sell0

Recent rating actions

2026-04-08Evercore ISI Group→ Outperform
2026-02-24Piper Sandler→ Neutral
2026-02-18JP Morgan→ Overweight
2026-02-18Baird→ Outperform
2026-02-06JP Morgan→ Overweight
2025-11-07JP Morgan→ Overweight

Material Events

DateEvent8-K
2026-08-14Officer / Director Changeread
2026-07-30Earnings Release, Exhibitsread
2026-07-10Reg FD Disclosure, Exhibitsread
2026-06-30Reg FD Disclosure, Exhibitsread
2026-05-27Reg FD Disclosure, Exhibitsread
2026-05-26Shareholder Voteread
2026-04-30Earnings Release, Exhibitsread
2026-04-09Reg FD Disclosure, Exhibitsread
2026-03-31Reg FD Disclosure, Exhibitsread
2026-03-20Material Agreement, Material Obligation…read
2026-02-17Earnings Release, Exhibitsread
2026-02-09Officer / Director Change, Reg FD Disclosure…read

Insider Trades

DateInsiderRoleActionSharesValue
2026-08-11Schechter Adam HPresident & CEOSell4.67K$1.50M
2026-08-04Summy Amy B.EVP, Chief Marketing OffiSell924$283.43K
2026-08-03Wilkinson Peter JSVP, Chief Accounting OffOption exercise1.34K$279.98K
2026-08-03Wilkinson Peter JSVP, Chief Accounting OffSell1.34K$413.75K
2026-08-03Wilkinson Peter JSVP, Chief Accounting OffSell82$25.36K
2026-07-02Vaughn Bryan TEVP and President, DiagnoSell234$66.97K
2026-07-02Kyle Kathryn WEVP, Chief Legal OfficerSell92$26.33K
2026-07-01Kyle Kathryn WEVP, Chief Legal OfficerWithheld for tax73$20.72K
2026-07-01Vaughn Bryan TEVP and President, DiagnoWithheld for tax93$26.40K
2026-07-01Vaughn Bryan TEVP and President, DiagnoOption exercise327—

Flow & Concentration

Insider 180d net-$4.02M
Insider buys / sells0 / 8
Insider biasSellers
13F holders8
Top-5 share99.1%
HHI4,233 (concentrated)

Top Holders

HolderValueShares
State Street Corp$1.09B3.91M
Fidelity / FMR LLC$533.36M1.90M
Capital Research / Capital World$144.50M516.07K
Millennium Management$67.21M240.04K
Citadel Advisors$30.43M108.67K
AQR Capital Management$16.93M61.00K
Bridgewater Associates$783.44K2.80K
T. Rowe Price Group$33.56K119.84K

As of 2026-06-30

Dividends

Yield (TTM)0.47%
$ / share (TTM)$1.44
5y CAGR—

Annual dividend per share

1994$0.17
2022$1.86
2023$2.68
2024$2.88
2025$2.88
2026$0.72

SEC Filings

DateFormDoc
2026-08-148-Kview
2026-08-124view
2026-08-064view
2026-08-0510-Qview
2026-08-054view
2026-07-308-Kview
2026-07-108-Kview
2026-07-064view
2026-07-064view
2026-06-308-Kview
2026-06-104view
2026-05-278-Kview
2026-05-268-Kview
2026-05-134view
2026-05-0410-Qview

The Long Run

FY 2009–2025 · 15 years

LineLatestCAGRTrend
Revenue$13.95B+9.2%
Gross profit$3.36B+3.9%
Operating income$725.60M-1.1%
Net income$418.00M-1.9%
Cash from ops$1.64B+4.7%

Indices

S&P 500

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$308.24$312.30$306.55$309.64821.50K
Sep 24$304.62$309.54$303.13$308.95784.90K
Sep 23$311.91$312.82$303.50$303.98909.20K
Sep 22$303.46$316.53$303.46$311.541.91M
Sep 21$321.95$323.84$318.94$320.99487.40K

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →